MedTrace Logo

Drug-Drug Interaction of SHR1459 With a Strong CYP3A Index Inducer (Rifampicin)

NCT04649723 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2021-01-11

No results posted yet for this study

Summary

This drug-drug interaction (DDI) study had been designed to investigate the effect of a strong CYP 3A index fan-inducer rifampicin on the pharmacokinetics of SHR1459 in Chinese healthy volunteers.

Conditions

  • Healthy Subjects, Drug-drug Interaction, Pharmacokinetics, SHR1459

Interventions

DRUG

Rifampin

single oral dose, 600 mg, fasted.

DRUG

SHR1459

single oral dose, 200 mg, fasted.

Sponsors & Collaborators

  • Jiangsu HengRui Medicine Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-11-24
Primary Completion
2020-12-14
Completion
2020-12-14

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04649723 on ClinicalTrials.gov